It's a positive from me. I'll be interested to see the cash balance and hopefully the cash burn is reduced and they have another 6-12 months to improve the retail marketing. At least there is some monetary value attached albeit by a stake in the company. I interpret another avenue outside waiting for a big pharma to buy/invest in the current DEP candidates. I'll await the May webinar which will be enlightening to see how much Cheryl has diverged from previous Management and strategy. Small mercies.
Ann: Starpharma and Medicxi Partnership Petalion Therapeutics, page-22
-
- There are more pages in this discussion • 140 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add SPL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
10.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $43.29M | |||
| Open | High | Low | Value | Volume |
| 10.0¢ | 10.5¢ | 10.0¢ | $12.03K | 116.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 3000 | 10.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 10.5¢ | 109616 | 3 |
View Market Depth
| Last trade - 16.10pm 12/07/2024 (20 minute delay) ? |
| SPL (ASX) Chart |